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Background: Idiopathic interstitial pneumonias (IIPs) are among the
most common complications in patients with lung cancer. In such
patients with cancer, the most serious expression of toxicity in Japan is
acute exacerbation of IIPs caused by anticancer treatment. Neverthe-
less, there has been no consensus and no evidence presented, regarding
optimal treatment for advanced lung cancer with IIP.
Patients and Methods: Chemotherapy-naive patients with ad-
vanced small cell lung cancer (SCLC) with IIP who were ineligible
for curative radiotherapy were enrolled. Patients received carbopla-
tin every 21 days at a dose of area under the curve 6.0 on day 1 and
etoposide at a dose of 100 mg/m2 on days 1 to 3.
Results: Between July 2002 and October 2008, 17 patients with
SCLC with IIP, including 14 men, eight of whom were diagnosed
with idiopathic pulmonary fibrosis, were enrolled and treated for a
mean of 3.5 cycles of carboplatin plus etoposide. One patient (5.9%;
95% confidence interval, 0–18.4%) with clinically confirmed idio-
pathic pulmonary fibrosis had acute exacerbation of IIPs associated
with the treatment. The overall response rate was 88.2%. The
median progression-free survival, median survival time, and 1-year
survival rate were 5.5 months, 8.7 months, and 29.4%, respectively.
Conclusion: This is the first report indicating that patients with
advanced SCLC with IIPs may benefit from chemotherapy. Patients
with advanced SCLC with IIP treated with etoposide and carboplatin
combination chemotherapy gain benefits, with safety equivalent to
that seen in patients without IIP. The results from this study would
support, on ethical grounds, the conduct of a large-scale study to
evaluate this regimen.
Key Words: Idiopathic interstitial pneumonias, Idiopathic pulmonary
fibrosis, Acute exacerbation, Small-cell lung cancer, Chemotherapy.
(J Thorac Oncol. 2011;6: 801–807)
Small cell lung cancer (SCLC) is characterized by a rapiddoubling time, a propensity for early dissemination, sig-
nificant sensitivity to chemotherapy and radiotherapy, and
accounts for approximately 15 to 20% of all cases of lung
cancer diagnosed. The majority of these patients have exten-
sive stage disease at the time of diagnosis. The standard
treatment for patients with extensive stage SCLC is systemic
chemotherapy with a combination of cisplatin and etoposide,
a regimen that yields a median survival of approximately 9
months and a 2-year survival of less than 10%.1–3 Neverthe-
less, elderly or poor performance status (PS) patients often
have poor tolerance for a cisplatin-containing regimen.
Therefore, carboplatin is widely used as an alternative.4,5
Idiopathic interstitial pneumonias (IIPs) seem to be
associated with lung carcinogenesis. In particular, the inci-
dence of lung cancer in patients with idiopathic pulmonary
fibrosis (IPF) is higher than that in the general population,
whose relative risk is reportedly 7 to 14.6–10 Kawasaki et al.11
reported that IPF was found in 7.5% of surgically resected
lung cancer cases. Recently, it has been recognized that IPF
is an independent risk factor for lung carcinogenesis.8
IIPs are usually characterized by slowly progressive
respiratory insufficiency. Nevertheless, some patients with
IIP experience acute exacerbations (AEs) generally charac-
terized by suddenly progressive and severe respiratory fail-
ure, with new lung opacities and pathological lesions of
diffuse alveolar damage. There are racial differences between
Mongolians (including Japanese) and whites in the frequency
of AE. Therefore, the concept of AE, which was first pro-
posed in Japan,12,13 has recently come to be recognized
globally.14–17 This clinical condition is lethal in many cases
and significantly affects the prognosis of patients with IIP,
because there is no established treatment for AE. In patients
with lung cancer combined with IIP (lung cancer [LC] with
IIP), idiopathic or iatrogenic AE frequently occurs after
various anticancer treatments. There are some retrospective
reports of exacerbation of a preexisting IIP after surgery,18–21
but there are only a few reports of chemotherapy that are
useful in designing a treatment strategy for LC with IIP. We
previously indicated that combination chemotherapy with
carboplatin and paclitaxel had significant antitumor efficacy
and permissible safety in treatment of non-small cell lung
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cancer (NSCLC) with IIP. In a limited sample size, this pilot
trial showed that the response rate was as good as that of
standard chemotherapy for NSCLC without IIP, and the
incidence (5.6%) of AE of IIPs was lower than that in
previous reports.22
The results of our retrospective study of LC with IIP
suggested that combined chemotherapy with carboplatin and
etoposide (CE) could be a candidate regimen for treatment of
patients with SCLC with IIP.23 We, therefore, conducted a
prospective study of CE to assess its acceptability, in terms of
safety and efficacy, in treatment of advanced SCLC with IIP.
PATIENTS AND METHODS
Study Design
Pathologically confirmed chemotherapy-naive patients
with SCLC with IIPs, for whom curative radiotherapy was
impossible, were eligible for enrollment. These did not in-
clude cases with unstable IIPs and acute/subacute IIPs. Pa-
tients receiving oxygen inhalation or using immunosuppres-
sive drugs such as steroids were eligible. Histological types
of lung cancer were defined according to the World Health
Organization Classification of 1999. Additional eligibility
criteria included Eastern Cooperative Oncology Group PS 0
to 2 and estimated life expectancy more than 3 months,
measurable lesion, adequate bone marrow, hepatic, and renal
functions. Written informed consent was obtained from all
enrolled patients. We obtained an approval in relationship to
institutional review boards in our institution.
We classified clinical IIP types into two groups: an IPF
pattern and a non-IPF pattern. The IPF pattern group consisted
of patients with histologically or clinically diagnosed IPF. All
other cases were placed in the non-IPF pattern group. Diagnosis
of IPF was made in accordance with American Thoracic Soci-
ety/European Respiratory Society criteria10 in patients previ-
ously diagnosed with usual interstitial pneumonia by either
histological evaluation of open-lung biopsy or transbronchial
lung biopsy specimens. In the absence of histological evidence,
diagnosis of an IPF pattern was based on evidence from a
high-resolution computed tomography (HRCT) scan of the chest
and other clinical features. Typical chest CT findings for the IPF
pattern were basal predominant, subpleural reticular abnormality
with traction bronchiectasis, honeycomb cysts, and no findings
of atypical features such as peribronchovascular nodules, iso-
lated cysts, or consolidation.24–26 In addition, the presence of
other typical clinical features, including bibasilar inspiratory
crackles, abnormal findings of pulmonary function tests indica-
tive of restrictive respiratory failure, and increased serum levels
of markers of damaged pneumocytes (i.e., lactate dehydrogenase
[LDH], C-reactive protein [CRP], KL-6, and surfactant protein
D [SP-D]) were investigated. Because we excluded sub-
jects in the acute and subacute phase of IIPs, all patients
had either clinical evidence of IPF or fibrotic nonspecific
interstitial pneumonia.
Cases were defined as having AE of IIPs if they
satisfied all the following criteria12,13: (1) exacerbation of
dyspnea within 1 month; (2) newly developed diffuse pulmo-
nary opacities on chest CT and/or chest x-ray; (3) decrease in
arterial oxygen tension (PaO2) of more than 10 mmHg under
similar conditions; and (4) absence of heart failure or infec-
tious lung diseases.
Study Treatment
Patients received carboplatin (area under the curve of
6.0) intravenously (IV) over 60 minutes on day 1, which was
followed by etoposide 100 mg/m2 IV over 60 minutes on
days 1 to 3, every 3 weeks. No prophylactic granulocyte
colony-stimulating factor (G-CSF) was planned. All patients
received standard supportive care, as appropriate. Treatment
was discontinued when one or more of the following events
occurred: disease progression, unacceptable toxicity such as
AE, patient refusal of further treatment, and investigator
decision to terminate treatment. Patients were monitored for
the development of AE for a minimum of 10 weeks after last
administration of etoposide.
Statistical Considerations
Because this study has been recognized as a pilot study
for a large-scale clinical trial, we considered that a large-scale
clinical trial could be undertaken when less than two patients
present with AE in a cohort of 17 enrolled patients (the
probability that 25% of the patients would have AE is
10%).
The primary end point was the incidence of treatment-
related AE. Secondary end points were toxicity, the objective
response rate (ORR), the median progression-free survival
(PFS), and the overall survival (OS). Evaluation was made in
compliance with National Cancer Institute common toxicity
criteria Version 3.0 for safety and with RECIST guidelines27
for antitumor activity. When diagnosis of AE was uncertain,
we performed the close inspection necessary for differential
diagnoses such as HRCT, evaluation of cardiac function, and
bacteriovirological examination. When AE was diagnosed,
active treatments such as steroid therapy with IV administra-
tion of methylprednisolone and/or administration of sivelestat
sodium were undertaken. Based on our previous report,23 AE
occurring within 10 weeks after final treatment was consid-
ered to be related to chemotherapy.
Examination values are reported as mean  standard
deviation. PFS was measured as the period from the start of
this treatment to the identifiable time for progression. Sur-
vival time was measured as the period from the start of this
treatment until death by all causes. PFS and OS were char-
acterized using the Kaplan-Meier method. Odds ratios (ORs)
and 95% confidence intervals (CIs) to assess the relative risk
of AE were calculated by logistic regression analysis. Result-
ing p values of less than 0.05 were considered to indicate
statistical significance.
RESULTS
Patient Characteristics
Between July 2002 and October 2008, a total of 17
Japanese patients (14 men and 3 women) were enrolled in this
study, and their characteristics are listed in Table 1. All
patients were evaluable for toxicity and survival assessments.
The median age at the time of diagnosis of lung cancer was
69 years; all patients were current or former smokers. Eight
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patients were clinically confirmed cases of IPF, and nine were
determined to be non-IPF pattern. There were no patients in
whom histological confirmation of interstitial pneumonias
was obtained. There were two patients who were diagnosed
as collagen-vascular disease after the study treatment (one
rheumatoid arthritis and one systemic sclerosis). One patient
had received immunosuppressive agents for IIPs. This patient
had a history of AE of IPF and was given 20 mg prednisolone
orally. The patient received the five cycles of chemotherapy
safely. Two patients routinely required oxygen inhalation for
IIPs. There were nine patients with stage IV and three
patients with stage IIIB. There were five patients with stage
IIIA in whom chemoradiotherapy was avoided.
Table 2 presents pretreatment demographic parameters
of patients. The mean serum levels of CRP and LDH were
1.96 mg/dl and 412 IU/L respectively. The mean PaO2 was
77.8 mmHg (range, 58–99) at rest under oxygen-free status.
The mean predicted vital capacity (%VC) in the respiratory
function test was 91.4% (range, 69–108). Positive incidence
and mean serum levels of KL-6 and SP-D were 86%, 956
U/ml and 33%, 111.9 ng/ml, respectively.
Treatment Efficacy
Table 3 summarizes the incidence of AE and the
antitumor effect data. Only one patient with clinical IPF
developed treatment-related AE (5.9%, 95% CI, 0–18.4%);
this occurred 9 weeks after completion of the five cycles of
chemotherapy where the efficacy amounted to a partial re-
sponse, and the patient died of the event after 4 weeks. The
survival time of this patient after registration was 38 weeks.
Two patients developed AE related to second-line chemo-
therapy, and one patient died due to AE. Moreover, AE
unrelated to treatment was observed in two patients; these
patients developed AE 8 months and over 3 months after last
administration of etoposide, respectively. Four of five pa-
tients with AE had clinical IPF. The incidence and mortality
from AE in the total follow-up period were 29.4% and 23.5%,
respectively.
The ORR was 88.2% (95% CI, 71–100%), comprising
one complete response and 14 partial responses. Stable and
progressive diseases were observed in one patient each.
Survival analysis performed in April 2010 showed that 14
patients had died. The median follow-up period was 9
months; we could not confirm the final outcome of one
patient. The median PFS was 5.5 months (Figure 1A), which
compared well with that of 4.8 months in the Japan Clinical
Oncology Group (JCOG) 9511 trial1 with cisplatin  etopo-
side for SCLC without IIP. In addition, the median survival
time (MST) was 8.7 months, and 1-year survival rate was
TABLE 1. Patient Characteristics
No. of patients 17
Gender
Male 14 82%
Female 3 18%
Age (yr)
Median 69
Range 53–80
PS (ECOG)
0 4 23%
1 10 59%
2 3 18%
Stage
IIIA 5 29%
IIIB 3 18%
IV 9 53%
IIPs pattern
IPF 8 47%
Non-IPF 9 53%
PS, performance status; ECOG, Eastern Cooperative Oncology Group; IIPs, idio-
pathic interstitial pneumonias; IPF, idiopathic pulmonary fibrosis.
TABLE 2. Baseline Demographic Data
Mean SD
CRP
mg/dl 1.96 3.29
LDH
IU/L 412 228
WBC
mm3 7540 2020
Pao2
Torr 77.8 11.8
KL–6
U/ml 956 563
Positive (500) 86 (%)
SP–D
ng/ml 111.9 75.3
Positive (110) 33 (%)
ANA
Positive (40) 57 (%)
%VC
Predicted 91.4 16.9
CRP, C-reactive protein; LDH, lactate dehydrogenase; WBC, white blood cells;
Pao2, arterial oxygen tension; ANA, antinuclear antibody; SP-D, surfactant protein D;
%VC, percent vital capacity; SD, standard deviation.
TABLE 3. Incidence of Acute Exacerbation and Objective
Response to Treatment
No. of patients 17
Acute exacerbation
Treatment related 1
To death 1
Second-line treatment related 2
To death 1
Treatment unrelated 2
To death 2
Objective response
CR  PR 15
SD 1
PD 1
Overall response rate 88.2%
CR, complete response; PR, partial response; SD, stable disease; PD, progressive
disease.
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29% (Figure 1B), compared with MST and 1-year survival
rate of JCOG 9511 of 9.4 months and 37.7%, respectively.
Toxicities
Treatment-related adverse events other than AE are
summarized in Table 4. The most common hematological
grades 3 and 4 adverse event was neutropenia (88.2%),
although febrile neutropenia was observed in two patients.
Nonhematological adverse events were generally mild, the
most common of which were nausea and vomiting. Only one
patient with nausea was grade 3. One grade 3 congestive
heart failure patient was also observed, which was considered
to have been possibly due to the treatment. The improvement
in condition of patients was good, and second-line treatment
was performed. A mean of 3.5 cycles of treatment was given
(range, 1–6 cycles), and 14 patients received three or more
cycles.
The Risk Factor of AE
In selecting patients, it can be recommended that those
cases at high risk of AE of IIPs be excluded with a view to
improvement of treatment safety. To evaluate the risk factor
of AE, we conducted an analysis that integrated this study
with that of NSCLC with IIP, which we reported previously.22
Integrated patient characteristics and AE status are listed in
Table 5. A total number of 35 patients were included in this
integrated analysis. There were 10 patients in total with AE
for the following reasons: first-line chemotherapy related,
two cases; second-line chemotherapy related, five cases; and
treatment unrelated, three cases. Thirty-two smokers (current
and former, 91%) and three never smokers (9%) were ob-
served. IPF and non-IPF patterns were observed in 14 (40%)
and 21 (60%) patients, respectively.
Univariate analyses of various risk factors, such as
clinical features and laboratory parameter, for AE in patients
who had LC with IIP are presented in Table 6. Regarding
clinical features, the ORs were 2.8 for men and 3.5 for elderly
patients (more than median age), but neither was significant.
The risk of AE in those with the IPF pattern was not
FIGURE 1. A, Progression-free survival (PFS) and (B) overall
survival (OS). Vertical bars indicate censored cases at the
data cutoff point. The median PFS, median survival time
(MST), and 1-year survival rate were 5.3 months, 10.6
months, and 22%, respectively.
TABLE 4. Treatment-Related Adverse Events Excluding
Acute Exacerbation
Toxicity
Grade
2
Grade
3
Grade
4
Grade
3–4 Percentage
Hematological
Leukocytopenia 11 3 14 82.4
Neutropenia 3 12 15 88.2
Febrile neutropenia 2 0 2 11.8
Anemia 4 4 1 5 29.4
Thrombocytopenia 1 4 1 5 29.4
Nonhematological
Nausea 4 1 0 1 5.9
Vomiting 1 0 0 0 0
Diarrhea 1 1 0 1 5.9
Congestive heart failure 1 1 5.9
Grade, National Cancer Institute Common Toxicity Criteria version 3.0.
TABLE 5. Patient Characteristics of SCLC and NSCLC
with IIP
No. of patients 35
Gender
Male 28 80%
Female 7 20%
Age (yr)
Median 69
Range 33–81
Performance status
0 11 31%
1 21 60%
2 3 9%
Smoking status
Current 25 71%
Former 7 20%
Never 3 9%
IIPs pattern
IPF 14 40%
Non-IPF 21 60%
Acute exacerbation
First line 2 5.7%
Second line 5 14.3%
Unrelated 3 8.6%
Total 10 28.6%
SCLC, small-cell lung cancer; NSCLC, non-small cell lung cancer; IIP, idiopathic
interstitial pneumonia; IPF, idiopathic pulmonary fibrosis.
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significantly higher than in those with a non-IPF pattern (OR:
3.19, p  0.13). Neither poor PS nor smoking status in-
creased the risk of AE. We carried out the analysis in various
additional settings (data not shown), but no statistically sig-
nificant risk factor was indentified in any of these cases.
DISCUSSION
Optimal chemotherapy for treatment of advanced LC
with IIP still remains controversial, because there have been
few reports focusing on AE of IIPs related to chemotherapy
for lung cancer. In the case of chemotherapy, the incidence of
treatment-related AE previously reported ranged from 8.7 to
21% in Japan.28–31 Therefore, AE is now increasingly being
recognized as a common clinical event for LC with IIP.
Nevertheless, there are conflicting views as to whether che-
motherapy for NSCLC with IIP can contribute to OS, because
its antitumor efficacy for NSCLC is less than that for SCLC.
In patients with SCLC with IIPs, we can expect that the
benefit of chemotherapy outweighs the risk of AE. On the
other hand, because the prognosis of SCLC without active
treatment is remarkably poor, SCLC shows considerable
sensitivity to chemotherapy. This is the first prospective study
to analyze the safety and efficacy of a specific regimen for
SCLC with IIP. In this pilot study of carboplatin combined
with etoposide for advanced SCLC with IIP, we observed an
incidence of treatment-related AE of 5.9%, median PFS of
5.5 months, and MST of 8.7 months.
Currently, platinum agent plus etoposide administered
every 3 weeks is one of the most widely used protocols for
advanced SCLC as the established standard regimen. Because
of the right heart overload, the patients with hypoxemia
and/or low pulmonary function often have the high risk of
pulmonary congestion. We selected the chemotherapy regi-
men based on carboplatin not cisplatin. Moreover, CE has
been reported to have good safety and efficacy in high-risk
patients such as the elderly and those with poor PS.4,5 We
observed an ORR of 88% and median PFS of 5.5 months,
which was comparable with the results of the randomized
phase III trial (JCOG 9702) in Japanese patients without IIPs
(ORR, 73%; median PFS, 5.2 months; MST, 10.6 months;
1-year survival rate, 41%).4 Nevertheless, the MST (8.7
months) and 1-year survival rate (29%) in this study would be
regarded as unsatisfactory for patients without interstitial
lung disease (ILD). Because of the difference between com-
paratively good PFS and unsatisfactory OS, we considered
that only 8 of 16 patients, excluding one patient for treatment-
related death, received second-line chemotherapy. We con-
sidered that the existence of IIPs had a negative influence in
performing second-line chemotherapy.
Attention is now being paid to the induction of AE of
IIPs by anticancer agents, following Japanese reports of ILD
developing after treatment with the epithelial growth factor
receptor tyrosine kinase inhibitor gefitinib. In 3166 Japanese
patients with advanced/recurrent NSCLC enrolled in a cohort
and nested case-control study, gefitinib-induced ILD was
manifested in 3.98%. More interestingly, that study demon-
strated that a predisposing background of preexisting IIPs
was an independent risk factor for developing AE, regardless
of gefitinib therapy or other chemotherapies (OR: 4.8–5.6).32
It has recently become a well-known phenomenon that
patients with IIP without lung cancer develop AE in the
normal course of the disease. Kim et al.33 reported retrospec-
tively that the 1-year frequency was 8.5% after diagnosis.
Kubo et al.34 reported a high incidence of AE (64%) in the
control group of a randomized study on the role of anticoag-
ulants. In another prospective randomized study on the role of
pirfenidone, Azuma et al.35 found a 14% incidence in 35
untreated patients during a 9-month follow-up period.
In some cases, it can be difficult in the individual
patient to differentiate AE of IIPs from lung cancer progres-
sion lymphangitic spread of the disease leading to diffuse
interstitial infiltrate. The frequency of AE of IIPs seems to be
higher in Japanese than in white. Serum KL-6 and SP-D
levels, markers of interstitial pneumonia, are common for
differential diagnosis in Japan. Another important differential
diagnosis is infectious diseases, such as pneumocystis ji-
roveci pneumonia with typical ground-glass opacities in a
multifocal or diffuse pattern in previously uninvolved area. A
TABLE 6. Odds Ratios of Acute Exacerbation of IIPs for
Various Risk Factors in the Patients Combined from Two
Studies
Risk Factors N OR 95% CI p
Gender
Male 35 2.84 0.30–27.3 0.37
Age (yr)
69a 35 3.50 0.73–16.9 0.12
PS
1 35 0.58 0.13–2.71 0.49
Type of IIPs
IPF 35 3.19 0.70–14.6 0.13
LDH (IU/L)
254a 35 0.62 0.14–2.73 0.52
CRP (mg/dl)
1.34a 35 0.34 0.07–1.61 0.17
WBC (mm3)
7820a 35 1.08 0.25–4.70 0.91
Pao2 (Torr)
80a 27 0.18 0.03–1.14 0.07
KL-6 (U/ml)
762a 32 0.56 0.12–2.54 0.45
Positive 0.88 0.17–4.54 0.87
SP-D (ng/ml)
94a 29 2.22 0.42–11.83 0.35
Positive 0.98 0.18–5.24 0.87
%VC predicted
80a 23 0.69 0.12–3.96 0.67
ANA
Positive 19 0.80 0.11–6.11 0.83
a Median.
IIP, idiopathic interstitial pneumonia; IPF, idiopathic pulmonary fibrosis; PS,
performance status; CRP, C-reactive protein; LDH, lactate dehydrogenase; WBC, white
blood cells; Pao2, arterial oxygen tension; SP-D, surfactant protein D; ANA, antinuclear
antibody; %VC, percent vital capacity; OR, odds ratio; CI, confidence interval.
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serum -D glucan is also used for the diagnosis of pneumo-
cystis jiroveci pneumonia.
For differential diagnosis of AE, there are various
infectious diseases, congestive heart failure, thromboembo-
lism, and carcinomatous progress. We routinely performed
the details of differential diagnosis of AE (i.e., HRCT, lung
function test, arterial blood gas, tumor markers, KL-6, SP-D,
evaluation of cardiac function by ultrasound cardiography
and brain natriuretic peptide, -D-glucan, D-dimer, and cul-
ture of sputum). HRCT is a useful modality in the diagnosis
of AE. Nevertheless, the exact incidence of AE from IIPs
may be overdiagnosed, because radiological changes cannot
specifically identify or diagnose histpathological changes.
Therefore, it would be recommended to identify histopatho-
logical/microbiological findings.
In this study, AE unrelated to anticancer treatment was
observed in two patients, and a further two patients had AE
related to second-line chemotherapy. The incidence of total
AE, including AE related to second-line chemotherapy and
AE unrelated to treatment at MST (8.7 months) and through-
out the follow-up period was 18% (3/17 patients) and 29%
(5/17 patients), respectively. Regardless of treatment, prolon-
gation of the observation period may increase the numbers of
AE manifested. In our previous study of NSCLC with IIP, AE
related to first-line treatment with carboplatin plus paclitaxel
was observed in one patient (5.6%), and AE was observed in
five patients (28%) in total. Although the incidence of first-
line chemotherapy-related AE was low in both studies, the
incidence of total AE may be high in comparison with its
incidence in IPF without lung cancer. The coexistence of lung
cancer and IIPs may also be potential risk factors for AE of IIPs.
Localization of active oxygen and a growth factor,
inflammatory cytokine, or vascularization factor to lung tis-
sue plays an important role in inducing inflammation.36 It
seems that these factors induced by anticancer treatment may
have been one cause of AE. Nevertheless, a useful predictive
risk factor for AE or drug-induced ILD has not yet been
identified. In our previous report, KL-6, SP-D, PaO2 and
%VC, which are considered to be markers of progression of
IIPs, were not predictive of developing AE. There was no
statistically significant difference in clinical background or
values for pretreatment parameters between those who did
and did not experience AE.22
We analyzed the predictors of development of AE for
patients in this study combined with those in our previous
pilot study for NSCLC.22 Throughout the follow-up period,
AE developed in 10 of 35 patients from the combined studies.
We conducted univariate analysis for gender, age, PS, smok-
ing status, IIP pattern as clinical factors and LDH, CRP,
white blood cells, PaO2, %VC, KL-6, SP-D, and antinuclear
antibody from examination data before initial chemotherapy.
Nevertheless, there was no statistically significant risk factor
for AE even under a variety of conditions. Nonetheless, in
male, elderly patients and in patients with an IPF pattern, a
nonsignificant trend toward a high risk of AE was indicated.
Moreover, as four of five patients with AE were clinically
diagnosed with IPF in this study, IPF may be the anticipated
risk factor for AE. On the other hand, using LDH, CRP,
KL-6, PaO2, and %VC as markers to reflect activity and
severity of IIPs, the opposite trends to those predicted by us
were indicated. It has been reported that the existence of focal
usual interstitial pneumonia, which was undetectable by con-
ventional chest CT, but confirmed in a biopsy specimen, was
closely related to AE after lung resection for lung cancer.37
These suggest that disease severity and progression of IIPs
are not always correlated with the risk of AE. Large-scale
studies are required for clarification.
No recommended regimen for LC with IIP has previ-
ously existed. To reduce the levels of toxicity and complica-
tions, especially various infectious diseases due to severe
neutropenia, and overhydration causing lung congestion, we
selected chemotherapy regimens based on carboplatin. The
incidence of myelosuppression in this study was not thereby
increased compared with that previously reported,1–5 and
nonhematological toxicities were mostly mild to moderate
and manageable. Although a high incidence of leukocytope-
nia and neutropenia was evident, the acceptability of this
treatment was good.
In conclusion, the combination chemotherapy of carbo-
platin plus etoposide used in this study during each 3-week
schedule was effective and safe for patients with advanced
SCLC with IIP. This is the first report indicating that chemo-
therapy for SCLC with IIP may be beneficial. To further
confirm the feasibility of carboplatin plus etoposide for ad-
vanced SCLC with IIP, we are now carrying out a more
large-scale clinical trial with detailed evaluation including
proteomic analysis, to detect a risk factor for AE.
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